CoChat

Assessing the cost‐effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy Model

Thokala, P., Kruger, J., Brennan, A., Basarir, H., Duenas, A., Pandor, A., Gillett, M., Elliott, J., Heller, S. · 2014 · Diabetic Medicine
Cited by 39

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Aims: To build a flexible and comprehensive long‐term Type 1 diabetes mellitus model incorporating the most up‐to‐date methodologies to allow a number of cost‐effectiveness evaluations. Methods: This paper describes the conceptual modelling, model implementation and model validation of the Sheffield Type 1 Diabetes Policy Model (version 1.0), developed through funding by the UK National Institute for Health Research as part of the Dose Adjustment for Normal Eating research programme. The model is an individual patient‐level simulation model of Type 1 diabetes and it includes long‐term microvascular (retinopathy, neuropathy and nephropathy) and macrovascular (myocardial infarction, stroke, revascularization and angina) diabetes‐related complications and acute adverse events (severe hypoglycaemia and diabetic ketoacidosis). The occurrence of these diabetes‐related complications in the model is linked to simulated individual patient‐level risk factors, including HbA 1c, age, duration of diabetes, lipids and blood pressure. Transition probabilities were modelled based on a combination of existing risk functions, published trials, epidemiological studies and individual‐level data from the Dose Adjustment for Normal Eating research programme. Results: The model takes a lifetime perspective, estimating the impact of interventions on costs, clinical outcomes, survival and quality‐adjusted life years. Validation of the model suggested that, for almost all diabetes‐related complications predicted, event rates were within 10% of the normalized rates reported in the studies used to build the model. Conclusions: The model is highly flexible and has broad potential application to evaluate the Dose Adjustment for Normal Eating research programme, other structured diabetes education programmes and other interventions for Type 1 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dme.12371

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 39

Metadata

Authors
Thokala, P., Kruger, J., Brennan, A., Basarir, H., Duenas, A., Pandor, A., Gillett, M., Elliott, J., & Heller, S.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2014-02-05
Volume
31
Issue
4
Pages
477-486
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2055173561
Cited by
39
References
3
FWCI
1.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessing the cost‐effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy Model. https://app.cochat.ai/papers/10.1111/dme.12371
The paper
Thokala, P., Kruger, J., Brennan, A., Basarir, H., Duenas, A., Pandor, A., Gillett, M., Elliott, J., & Heller, S. (2014). Assessing the cost‐effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy Model. Diabetic Medicine. https://doi.org/10.1111/dme.12371

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.